A single-arm, multi-center, open-label proof of concept safety and efficacy study of FCR001 cell-based therapy in adults with rapidly progressive diffuse cutaneous systemic sclerosis at risk for organ failure
Clinical Trial Grant
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Talaris Therapeutics
Start Date
February 28, 2023
End Date
February 27, 2028
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Talaris Therapeutics
Start Date
February 28, 2023
End Date
February 27, 2028